A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 in Combination With other Therapies in Subjects With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous MTAP-deletion Master
Clinical Trial Grant
Awarded By
Amgen, Inc.
Start Date
January 27, 2025
End Date
January 14, 2030
Awarded By
Amgen, Inc.
Start Date
January 27, 2025
End Date
January 14, 2030